Royal Philips, Celsion collaborate on cancer drug delivery

By Mass High Tech Staff

Report: Philips Electronics to set up North American HQ in Andover [July 18, 2008]

Former Color Kinetics inks license deal with Virginia firm [March 25, 2008]

The Pitch: HNHSoft looks to translate a funding [March 3, 2008]

Philips adds Fall River firm Lightolier to family [February 18, 2008]

Dutch technology firm Royal Philips Electronics NV, which has its North American headquarters in Andover, and Celsion Corp., a Columbia, Md., biotech, have entered into a multi-year partnering agreement to combine their technologies in the fight against cancer.

The companies will combine Royal Philips Electronics’ (NYSE: PHG) magnetic resonance imaging guided ultrasound technology and Celsion’s drug delivery platform. The systems will be used to administer high concentrations of drugs to target cancerous tumors. Celsion’s (Nasdaq: CLSN) primary drug in development is a cancer-fighting product called ThermoDox. The drug is a heat-sensitive liposomal encapsulation of the chemotherapy agent doxorubicin. The drug is released when hyperthermia is induced.

In July, Royal Philips Electronics moved its North American headquarters from New York City to Andover, the site of Philips Healthcare, a medical device manufacturer and subsidiary of Royal Philips Electronics that employs 2,200 workers.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.